Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy (PatACT)

This randomised, quadruple-blind, placebo-controlled trial (n=40) will evaluate the safety, feasibility, and efficacy of psilocybin-assisted therapy in adults aged 18–65 with persistent post-concussion symptoms (PPCS). Participants will receive either a high dose (25mg) or a low dose (1mg) of psilocybin and undergo 5–6 weekly sessions of BrainACT, an adapted form of Acceptance and Commitment Therapy (ACT) for individuals with acquired brain injury.

The study, conducted by the University of Calgary, aims to determine the safety of psilocybin through adverse event monitoring and feasibility through recruitment, adherence, and retention rates.

Efficacy will be assessed by measuring changes in PPCS burden using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) at 1 week, 4 weeks, 3 months, and 6 months post-dosing. Secondary outcomes include assessments of headache, dizziness, mood, anxiety, post-traumatic stress, cognitive flexibility, emotional regulation, and quality of life. The trial is expected to begin in October 2024 and conclude in March 2027.

Topic Safety Traumatic Brain Injury
Compound Psilocybin Placebo
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Calgary
The University of Calgary, located in Alberta, Canada, is a comprehensive academic and research institution.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.